BUFFALO, NY--(MARKET WIRE)--Jul 17, 2007 -- Cleveland BioLabs, Inc. (NasdaqCM:CBLI - News) (Boston:CFB - News) today announced that it has submitted responses to two Requests for Information (RFI) from the Department of Health and Human Services (HHS) and National Institute of Allergy and Infectious Diseases (NIAID) addressing medical countermeasures for neutropenia (low levels of neutrophils, a type of white blood cell) and thrombocytopenia (low platelet count) arising from Acute Radiation Syndrome (ARS).